|
Clinical characteristics of the population studied |
||||
| Background metformin |
Background sulfonylurea |
|||
|
|
|
|||
| + rosiglitazone |
+ sulfonylurea |
+ rosiglitazone |
+ metformin |
|
|
|
||||
| Participants (n) |
176 |
165 |
160 |
167 |
| Age (yr) |
57 ± 8 |
57 ± 8 |
60 ± 8 |
58 ± 8 |
| Male (n (%)) |
80 (45) |
86 (52) |
83 (52) |
77 (46) |
| Europid (n (%)) |
175 (> 99) |
165 (100) |
160 (100) |
167 (100) |
| Body weight (kg) |
92 ± 17 |
94 ± 16 |
86 ± 13 |
84 ± 16 |
| BMI (kg/m2) |
33 ± 5 |
32 ± 5 |
31 ± 4 |
30 ± 5 |
| Time from diabetes diagnosis (yr) |
5.7 ± 3.8 |
5.9 ± 3.6 |
7.7 ± 5.1 |
7.1 ± 5.1 |
| HbA1c (%) |
7.8 ± 0.6 |
7.8 ± 0.8 |
7.9 ± 0.7 |
8.0 ± 0.8 |
| Fasting plasma glucose (mmol/l) |
9.2 ± 2.1 |
9.7 ± 2.3 |
10.0 ± 2.4 |
10.2 ± 2.4 |
| Homeostasis model assessment %S (%) |
68 (42, 106) |
64 (42, 108) |
64 (47, 88) |
63 (42, 93) |
| Hypertension* (n (%)) |
145 (82) |
138 (84) |
139 (87) |
141 (84) |
| Treated with antihypertensive drugs |
119 (68) |
112 (68) |
104 (65) |
114 (68) |
| Ambulatory systolic BP (mmHg) |
||||
| 24-hour |
132 ± 14 |
134 ± 16 |
132 ± 13 |
132 ± 14 |
| Day-time |
136 ± 14 |
138 ± 15 |
135 ± 13 |
136 ± 14 |
| Night-time |
126 ± 15 |
128 ± 18 |
126 ± 14 |
127 ± 15 |
| Ambulatory diastolic BP (mmHg) |
||||
| 24-hour |
78 ± 8 |
78 ± 9 |
76 ± 8 |
76 ± 8 |
| Day-time |
81 ± 8 |
82 ± 10 |
79 ± 8 |
79 ± 8 |
| Night-time |
72 ± 9 |
73 ± 10 |
71 ± 9 |
71 ± 9 |
| Ambulatory heart rate (beat/min) |
||||
| 24-hour |
76 ± 10 |
75 ± 9 |
74 ± 11 |
75 ± 10 |
| Day-time |
81 ± 11 |
80 ± 10 |
79 ± 12 |
78 ± 11 |
| Night-time |
70 ± 9 |
69 ± 9 |
68 ± 10 |
69 ± 9 |
|
Number (percent) or mean ± SD, or median (IQR). *Medical history or average baseline day-time ABPM > 135/85 mmHg | ||||
Komajda et al. Cardiovascular Diabetology 2008 7:10 doi:10.1186/1475-2840-7-10 |
||||